期刊文献+

颈动脉超声检查在心血管高危人群中的临床应用 被引量:3

Clinical application of carotid ultrasound in cardiovascular high-risk groups
下载PDF
导出
摘要 目的:颈动脉超声检查对不同级别的心血管高危患者的临床应用观察。方法:随机选取我院2008年12月-2010年1月的心血管高危患者120例,根据患者颈动脉内膜中层厚度分为观察组(60例,IMT≤1.0mm)与对照组(60例IMT1.1-1.5mm),对两组患者进行冠状动脉造影检查,比较两组患者心血管危险因素、冠状动脉血管病变情况和血液生化指标。结果:观察组患者危险因素数目和心血管事件数低于对照组,两组患者比较差异有统计学意义(P【0.05)。结论:颈动脉超声检查可以估测心血管疾病高危人群冠状动脉血管病变的程度,操作简单,可参考价值高,值得在临床推广。 Objective:Carotid artery ultrasound clinical observation on the different levels of cardiovascular high-risk patients.Methods:A hospital in December 2008-January 2010,120 cases of high-risk cardiovascular patients,divided into two groups(60 cases of patients with carotid artery intima-media thickness,IMT≤1.0mm) with the control group(60 cases 1.1-1.5mm),two groups of patients,coronary angiography,the number of patients with cardiovascular risk factors were compared between the two groups,coronary vascular disease situation and the blood biochemical indices.Results:The number of patients risk factors and cardiovascular events number is lower than the control group,two groups of patients the difference was statistically significant(P<0.05).Conclusion:Carotid ultrasonography can estimate the extent of cardiovascular disease at high risk of coronary artery lesions,simple operation,high reference value,it is worth in clinical practice.
作者 谢敏
出处 《中国保健营养(下半月)》 2012年第4期721-722,共2页 China Health Care & Nutrition
关键词 颈动脉 超声检查 心血管高危人群 冠状动脉造影 危险因素 Carotid artery Ultrasound High cardiovascular risk factors Coronary angiography Risk factors
  • 相关文献

参考文献4

二级参考文献12

  • 1Dupuis J, Tardif J C, Cernacek P, et al. Theroux cholesterol reduction rapidly improves endothelial function of the RECIFE (Reduction of cholesterol in ische-mial and function of the endothelium) trial. Circulation,1999,99: 3227- 3233.
  • 2The Long-term Intervention with Pravastatin in Ischaemic Disease(LIPID) study group. Prevention of cardiovascular events and a broad range of initial cholesterol levels. N EnglJ Med, 1998,339:1349-1357.
  • 3Pederson J R, Olsson A G, Faergeman V, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 1998,97:1453-1460.
  • 4FlakerG C, Warnica J W, Sacks F M,et al. For the Cholesterol and Recurrent Event(CARE) investigators.Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. J Am Coll Cardiol, 1999,34:106- 112.
  • 5Schwartz G G, Olsson A G, Ezekowitz M D, et al.Effects of atorvastatin on early recurrent ische mic events in acute coronary syndrome. The MIRACL study: A randomized controlled trial. JAMA, 2001,285:1711-1718.
  • 6Maron D J, Fazio S, Linton M F. Current perspectives on statins. Circulation, 2000,101: 207- 213.
  • 7Bustos C, Hernandez-Presa M A, Ortego M, et al.HMG-GoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol, 1998,32:2057-2064.
  • 8Laufs U, Liao J K. Post-transcriptional regulation of endothelial nitric oxide synthasc mRNA stability by Rho GTPase. J Biol Chem, 1998,273:24266-24271.
  • 9Williams J K, Sukova G K, Herrington D M, et al.Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol, 1998,31: 684- 691.
  • 10Rose.,RS,胡予.他汀类药物的抗粥样血栓特性对心血管事件减少的意义[J].美国医学会杂志(中文版),1999,18(3):110-115. 被引量:20

共引文献49

同被引文献19

引证文献3

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部